Skip to main content

Table 2 Drug-related adverse events

From: Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment

Variable OSI (n = 85 AEs involving 48 patients) AFA (n = 109 AEs involving 59 patients) p valuea
  All grades (%)  ≥ Grade 3 (%) All grades (%)  ≥ Grade 3 (%) All grades (%)  ≥ Grade 3 (%)
Diarrhoea 24 (28.2) 8 (9.4) 47 (43.1) 25 (22.9) 0.03* 0.13
Rash 22 (25.9) 5 (5.9) 18 (16.5) 7 (6.4) 0.11 0.88
Dry skin 18 (21.2) 6 (7.1) 12 (11.0) 5 (4.6) 0.52 0.46
Paronychia 11 (12.9) 0 (0.0) 6 (5.5) 0 (0.0) 0.07 NA
Alopecia 3 (3.5) 0 (0.0) 15 (13.8) 6 (5.5) 0.02* 0.03*
Asthenia 2 (2.4) 0 (0.0) 6 (5.5) 0 (0.0) 0.27 NA
Decreased appetite 5 (5.8) 0 (0.0) 5 (4.6) 0 (0.0) 0.69 NA